-- 西班牙電力公司伊維爾德羅拉(Iberdrola)週三公佈,第一季電力產量年增1.6%,主要得益於裝置容量成長3.8%。 截至3月31日的第一季度,淨發電量為36.106太瓦時(TWh),其中25.62太瓦時來自再生能源。 離岸風電發電量激增42%,達2.639太瓦時;太陽能發電量增加1.7%,達1.703太瓦時。另一方面,陸域風電發電量下降2.7%,至11.775太瓦時;水電發電量下降1.1%,至9.366太瓦時。 燃氣聯合循環發電廠的發電量激增42.5%,達到3.453太瓦時;而核電發電量則下降12.7%,至5.464太瓦時。 同時,伊維爾德羅拉的裝置容量年增3.8%,達到58.877吉瓦,主要得益於新增的儲能、太陽能和風能裝置容量。 同期,電力和天然氣供應量分別成長10.6%至27.132太瓦時和2.4%至15.196太瓦時。 在電網業務方面,公司輸送的電力成長9.7%至68.645太瓦時,主要得益於供應點數量增加8.7%至3,710萬個。英國市場成長最為顯著,電力輸送量飆升72.6%至14.687太瓦時,供應點數量增加69.4%至610萬個。 另一方面,由於供應點數量減少0.7%至100萬個,美國市場的天然氣輸送量下降5.5%至25.582太瓦時。
Related Articles
ICBC Sells 50 Billion Yuan Bonds
Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.
DFZQ's Profit Climbs 11% in Q1
Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.
Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.